

Re: EntreMed Presents Results for Panzem(R) NCD Phase 2 Ovarian Cancer Study

Source: <http://sci.tech-archive.net/Archive/sci.med.diseases.cancer/2007-10/msg00050.html>

- *From:* J <nswex@nald'anon>
 - *Date:* Wed, 24 Oct 2007 12:21:22 -0400
-

J wrote:

<
<http://money.cnn.com/news/newsfeeds/articles/prnewswire/NEW01424102007-1.htm>

EntreMed Presents Results for Panzem(R) NCD Phase 2 Ovarian Cancer Study
Results Demonstrate Activity in Advanced Disease
October 24, 2007: 07:00 AM EST

ROCKVILLE, Md., Oct. 24 /PRNewswire-FirstCall/ --- EntreMed, Inc. , a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the presentation of results for its Phase 2, open-label study for Panzem(R) NCD (2ME2 or 2-methoxyestradiol) in patients with ovarian cancer. The results were presented by Dr. Daniela Matei, principal investigator for the study representing the Hoosier Oncology Group, at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held this week in San Francisco, California.

(Logo: <http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO>)

Data from the Phase 2 study demonstrate that Panzem(R) NCD, administered as a single agent in patients with platinum refractory epithelial ovarian cancer, resulted in one patient with a confirmed partial response of their CA- 125. Five patients, out of the 18 patients enrolled, achieved stable disease lasting greater than three months. Panzem(R) NCD was well tolerated and no significant neuropathy, myelosuppression or thromboembolic side effects were reported. Three patients remained on study for more than 6 months and two of these patients are still on study.

8 studies were found.

<http://clinicaltrials.gov/ct/show/NCT00030095>

1. Completed 2-Methoxyestradiol in Treating Patients With Advanced Solid Tumors

Re: EntreMed Presents Results for Panzem(R) NCD Phase 2 Ovarian Cancer Study

Condition: Unspecified Adult Solid Tumor, Protocol Specific

<http://clinicaltrials.gov/ct/show/NCT00028821>

2. Completed 2-Methoxyestradiol in Treating Patients With Advanced Solid Tumors

Conditions: Multiple Myeloma and Plasma Cell Neoplasm; Unspecified Adult Solid Tumor, Protocol Specific

<http://clinicaltrials.gov/ct/show/NCT00306618>

3. Active, not recruiting Safety and Efficacy Study of Panzem NCD to Treat Glioblastoma

Condition: Recurrent Glioblastoma Multiforme

<http://clinicaltrials.gov/ct/show/NCT00328497>

4. Active, not recruiting A Combination Study to Determine the Safety and Efficacy of Panzem NCD With Avastin in Metastatic Carcinoid Tumors

Condition: Carcinoid Tumor

<http://clinicaltrials.gov/ct/show/NCT00444314>

5. Recruiting Phase 2 Study of Panzem® NCD Alone and Combined With Sunitinib Malate in Patients With Metastatic Renal Cell Carcinoma

Condition: Metastatic Renal Cell Carcinoma

<http://clinicaltrials.gov/ct/show/NCT00394810>

6. Active, not recruiting Efficacy and Pharmacodynamic Study of Panzem® NCD in Patients With Hormone-Refractory Prostate Cancer

Condition: Prostate Cancer

<http://clinicaltrials.gov/ct/show/NCT00400348>

7. Active, not recruiting Safety and Efficacy Study of Panzem® Nanocrystal Colloidal Dispersion in Patients With Ovarian Cancer

Condition: Ovarian Cancer

<http://clinicaltrials.gov/ct/show/NCT00481455>

8. Recruiting Phase 2 Study of Panzem NCD in Combination With Fixed-Dose Temozolomide to Patients With Recurrent GBM

Condition: Recurrent Glioblastoma Multiforme

.